Drugs moving into the clinic: 2
The second in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| AEterna Zentaris | ZEN-012 | Cancer: solid tumors & lymphoma | tubulin and topoisomerase II inhibitor. Also pro-apoptotic and anti-angiogenic properties |
| BioWa & Medarex | MDX-1401 | Cancer: lymphoma | antibody for CD30-positive tumours with increased Fc receptor mediated activity |
| ImClone Systems | IMC-3G3 | Cancer: solid tumours | human IgG1 monoclonal antibody targeting platelet derived growth factor receptor alpha (PDGFR?) |
| Humanetics Corporation | BIO 300 | prevention and treatment of Acute Radiation Syndrome (ARS) | tyrosine kinase inhibitor |
| Merck | MK-6592 | Cancer: advanced solid tumours | Aurora kinase inhibitor |
| Speedel | SPP1148 | Hypertension & related disorders | renin inhibitor |
| Targacept | TC-2216 | depression and anxiety disorders | Inhibits alpha4beta2 neuronal nicotinic receptors to modulate release of neuro- transmitters involved in mood regulation |
